National Health (Ceasing of Co-marketed Brands) Determination 2013 (No. 1) (No. PB 20 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L00577

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
PB 20 of 2013
 
National Health (Ceasing of Co-marketed Brands) Determination 2013 (No. 1)1
 
National Health Act 1953
___________________________________________________________________________
 
I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, determine under subsection 84AE(3B) of the National Health Act 1953 (“the Act”) that the brands of pharmaceutical items specified in columns 2 and 3 of an item specified in column 1 of the Schedule cease to be co-marketed brands of a pharmaceutical item.
 
 
This instrument commences on 1 April 2013;
 
Dated         27             March 2013
 
 
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health and Ageing
 
 
 
 
Schedule
 
Column 1
Column 2
Column 3

Item
Listed brand of pharmaceutical item
Listed brand of pharmaceutical item

 
Brand
Drug
Form
Manner of administration
Brand
Drug
Form
Manner of administration

1
Avapro
Irbesartan
Tablet 75 mg
Oral
Karvea
Irbesartan
Tablet 75 mg
Oral

2
Avapro
Irbesartan
Tablet 150 mg
Oral
Karvea
Irbesartan
Tablet 150 mg
Oral

3
Avapro
Irbesartan
Tablet 300 mg
Oral
Karvea
Irbesartan
Tablet 300 mg
Oral

 
Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.comlaw.gov.au.